That is what an evidence base looks like for a GHRH analogue: hundreds of randomised patients, a year of treatment, a hard endpoint, a regulators review, and an honest negative finding about durability
The two most clinically relevant GHRH peptides are: CJC-1295 (without DAC): Promotes physiologic GH pulses, often paired with a growth hormonereleasing peptide (GHRP) like Ipamorelin for synergistic effects
Side effects are rare and mild, most commonly involving slight bruising or itching at the injection site
Together these molecules constitute the **reference pairing** in tendon, ligament, muscle and vascular repair research: two complementary mechanisms of action, one shared angiogenic vector, and dramatically expanded tissue coverage
As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1
Modified GRF (1-29) + Ipamorelin Chemical Formula: Composite peptide blend (multiple sequences) CAS Number: Mixture (individual components vary) Molecular Weight: Composite (component-dependent) Peptide Length: Multiple peptides (varied amino acid lengths) Purity: 99.0% (validated by Certificate of Analysis for each component) Appearance: White to off-white lyophilized powder Solubility: Fully soluble in water (HO) Quality Verification: Confirmed by RP-HPLC analysis Storage Conditions: Store dry at 28 C
